Tepezza (teprotumumab-trbw) Continuation Therapy
Customize your policy alerts
Sign up for all Mass General Brigham Health Plan policy alerts
Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization and continuation coverage for Tepezza under the medical benefit for adults with thyroid eye disease, including documentation, clinical criteria, dosing limits, and reauthorization requirements.
Clinical rationale for using Tepezza instead of Lumvoa was added as a coverage criterion.
Confirmation that the member has no history of treatment with Lumvoa was added as a coverage criterion.
The policy was updated with formatting and reference changes during the November 2026 review.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.